生意社4月15日讯 美国食品药品监督管理局宣布，为履行蒙特利尔协议中保护臭氧层的义务，7种含有破坏臭氧层氟氯化烃类物质的吸入剂会逐渐从美国市场消失，这些药物是用来治疗哮喘和慢性阻塞型肺炎（COPD），其中氟氯化烃的作用是将药物带入到患者的肺部，现在有了不含有氟氯化烃的新药物可替代。
受影响的药物及其限期退出日
| Inhaler Medication | Last Date to be manufactured, sold or dispensed in U.S. | Manufacturer |
| Tilade Inhaler (nedocromil) | June 14, 2010 | King Pharmaceuticals |
| Alupent Inhalation Aerosol (metaproterenol) | June 14, 2010 | Boehringer Ingelheim Pharmaceuticals |
| Azmacort Inhalation Aerosol (triamcinolone) | Dec. 31, 2010 | Abbott Laboratories |
| Intal Inhaler (cromolyn) | Dec. 31, 2010 | King Pharmaceuticals |
| Aerobid Inhaler System (flunisolide) | June 30, 2011 | Forest Laboratories |
| Combivent Inhalation Aerosol (albuterol and ipratropium in combination) | Dec. 31, 2013 | Boehringer Ingelheim Pharmaceuticals |
| Maxair Autohaler (pirbuterol) | Dec. 31, 2013 | Graceway Pharmaceuticals |
